Rajeev Vibhakar
Concepts (399)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 37 | 2024 | 197 | 9.550 |
Why?
| Cerebellar Neoplasms | 27 | 2024 | 155 | 7.360 |
Why?
| Glioma | 16 | 2025 | 352 | 3.430 |
Why?
| Rhabdoid Tumor | 9 | 2022 | 86 | 2.820 |
Why?
| Gene Expression Regulation, Neoplastic | 25 | 2025 | 1333 | 2.700 |
Why?
| Brain Neoplasms | 22 | 2025 | 1149 | 2.690 |
Why?
| Radiation Tolerance | 7 | 2022 | 97 | 2.500 |
Why?
| Cell Cycle Proteins | 8 | 2022 | 580 | 2.280 |
Why?
| Cell Proliferation | 25 | 2025 | 2335 | 1.730 |
Why?
| Teratoma | 5 | 2022 | 103 | 1.590 |
Why?
| Cell Line, Tumor | 32 | 2025 | 3160 | 1.580 |
Why?
| Proto-Oncogene Proteins c-myc | 5 | 2024 | 129 | 1.400 |
Why?
| Protein-Tyrosine Kinases | 4 | 2020 | 430 | 1.390 |
Why?
| Ependymoma | 10 | 2024 | 176 | 1.310 |
Why?
| Pyrazoles | 7 | 2022 | 400 | 1.190 |
Why?
| Nuclear Proteins | 9 | 2023 | 648 | 1.190 |
Why?
| Apoptosis | 19 | 2024 | 2437 | 1.130 |
Why?
| Proto-Oncogene Proteins | 4 | 2022 | 634 | 1.120 |
Why?
| Biomarkers, Tumor | 9 | 2021 | 1182 | 1.040 |
Why?
| Pyrimidines | 8 | 2019 | 444 | 0.970 |
Why?
| Cyclin-Dependent Kinase 6 | 4 | 2020 | 39 | 0.960 |
Why?
| Molecular Targeted Therapy | 4 | 2021 | 387 | 0.960 |
Why?
| Brain Stem Neoplasms | 4 | 2021 | 89 | 0.950 |
Why?
| Antineoplastic Agents | 10 | 2022 | 2058 | 0.930 |
Why?
| Radiation-Sensitizing Agents | 2 | 2016 | 40 | 0.910 |
Why?
| Cell Transformation, Neoplastic | 2 | 2019 | 325 | 0.860 |
Why?
| Neoplastic Stem Cells | 4 | 2025 | 384 | 0.840 |
Why?
| Genes, myc | 3 | 2020 | 50 | 0.830 |
Why?
| MicroRNAs | 5 | 2020 | 671 | 0.820 |
Why?
| Cellular Senescence | 3 | 2019 | 173 | 0.810 |
Why?
| Pyrimidinones | 4 | 2020 | 102 | 0.810 |
Why?
| Hedgehog Proteins | 7 | 2022 | 187 | 0.810 |
Why?
| Cell Cycle | 11 | 2017 | 581 | 0.750 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 61 | 0.750 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.730 |
Why?
| Receptor, trkB | 1 | 2021 | 31 | 0.720 |
Why?
| Anilides | 3 | 2019 | 72 | 0.710 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 60 | 0.700 |
Why?
| DNA Repair | 2 | 2024 | 205 | 0.700 |
Why?
| Gene Expression Profiling | 15 | 2024 | 1687 | 0.680 |
Why?
| Central Nervous System Neoplasms | 4 | 2019 | 147 | 0.680 |
Why?
| SMARCB1 Protein | 2 | 2020 | 18 | 0.670 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 36 | 0.670 |
Why?
| Deoxycytidine | 1 | 2020 | 164 | 0.630 |
Why?
| Pteridines | 2 | 2016 | 22 | 0.620 |
Why?
| Cerebellum | 5 | 2022 | 217 | 0.610 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 466 | 0.600 |
Why?
| Humans | 86 | 2025 | 128524 | 0.600 |
Why?
| Oligonucleotide Array Sequence Analysis | 10 | 2016 | 756 | 0.590 |
Why?
| Transcription Factors | 6 | 2023 | 1631 | 0.580 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 507 | 0.580 |
Why?
| Histones | 4 | 2020 | 581 | 0.580 |
Why?
| Glioblastoma | 3 | 2023 | 320 | 0.570 |
Why?
| Xenograft Model Antitumor Assays | 7 | 2024 | 810 | 0.550 |
Why?
| RNA, Small Interfering | 4 | 2022 | 571 | 0.540 |
Why?
| Blotting, Western | 8 | 2019 | 1168 | 0.540 |
Why?
| Vinblastine | 1 | 2016 | 68 | 0.530 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 31 | 0.530 |
Why?
| Radiation, Ionizing | 3 | 2022 | 75 | 0.530 |
Why?
| Bilirubin | 1 | 2016 | 92 | 0.530 |
Why?
| Vincristine | 1 | 2016 | 110 | 0.520 |
Why?
| Cell Survival | 8 | 2019 | 1077 | 0.510 |
Why?
| Infratentorial Neoplasms | 3 | 2024 | 60 | 0.510 |
Why?
| Tumor Cells, Cultured | 7 | 2020 | 927 | 0.490 |
Why?
| Enzyme Inhibitors | 6 | 2020 | 811 | 0.490 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 134 | 0.480 |
Why?
| Child | 31 | 2025 | 20721 | 0.480 |
Why?
| Mutation | 7 | 2022 | 3692 | 0.480 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2012 | 63 | 0.470 |
Why?
| Transcriptome | 5 | 2022 | 881 | 0.460 |
Why?
| RNA, Messenger | 7 | 2014 | 2674 | 0.440 |
Why?
| Histone Deacetylase Inhibitors | 3 | 2023 | 206 | 0.440 |
Why?
| Mice | 18 | 2025 | 16579 | 0.430 |
Why?
| Repressor Proteins | 3 | 2022 | 400 | 0.390 |
Why?
| Piperazines | 3 | 2022 | 334 | 0.370 |
Why?
| Child, Preschool | 18 | 2021 | 10373 | 0.360 |
Why?
| Prognosis | 9 | 2020 | 3780 | 0.350 |
Why?
| Azepines | 3 | 2019 | 88 | 0.350 |
Why?
| Epigenesis, Genetic | 4 | 2021 | 616 | 0.350 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 937 | 0.350 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2020 | 17 | 0.340 |
Why?
| Intracellular Space | 1 | 2010 | 71 | 0.340 |
Why?
| Animals | 19 | 2025 | 34501 | 0.340 |
Why?
| Chromatin | 4 | 2020 | 478 | 0.340 |
Why?
| Genes, Tumor Suppressor | 2 | 2007 | 86 | 0.330 |
Why?
| Neoplasm Proteins | 2 | 2012 | 421 | 0.330 |
Why?
| Reactive Oxygen Species | 2 | 2022 | 579 | 0.320 |
Why?
| Cisplatin | 3 | 2016 | 297 | 0.320 |
Why?
| Real-Time Polymerase Chain Reaction | 4 | 2014 | 326 | 0.310 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1565 | 0.310 |
Why?
| Drug Screening Assays, Antitumor | 4 | 2021 | 194 | 0.300 |
Why?
| Cell Differentiation | 6 | 2022 | 1883 | 0.300 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2019 | 70 | 0.300 |
Why?
| Protein Kinase Inhibitors | 2 | 2014 | 872 | 0.300 |
Why?
| Quinazolines | 2 | 2022 | 242 | 0.290 |
Why?
| NF-kappa B | 4 | 2023 | 651 | 0.290 |
Why?
| DNA-Binding Proteins | 3 | 2017 | 1415 | 0.270 |
Why?
| B7 Antigens | 2 | 2020 | 14 | 0.270 |
Why?
| Mice, Nude | 3 | 2020 | 682 | 0.270 |
Why?
| Aurora Kinases | 3 | 2012 | 29 | 0.270 |
Why?
| Aurora Kinase A | 3 | 2012 | 55 | 0.270 |
Why?
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 485 | 0.270 |
Why?
| Signal Transduction | 9 | 2021 | 4829 | 0.270 |
Why?
| Combined Modality Therapy | 6 | 2019 | 1209 | 0.260 |
Why?
| Single-Cell Analysis | 4 | 2022 | 274 | 0.260 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2019 | 214 | 0.260 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2020 | 47 | 0.260 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 41 | 0.250 |
Why?
| Autophagy | 2 | 2019 | 266 | 0.250 |
Why?
| Neoplasm Recurrence, Local | 4 | 2022 | 957 | 0.250 |
Why?
| Epigenomics | 3 | 2020 | 111 | 0.240 |
Why?
| Triazoles | 2 | 2019 | 151 | 0.240 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 371 | 0.240 |
Why?
| Gene Fusion | 1 | 2025 | 24 | 0.240 |
Why?
| Bone Morphogenetic Proteins | 2 | 2019 | 129 | 0.240 |
Why?
| Protein-Arginine N-Methyltransferases | 1 | 2025 | 28 | 0.240 |
Why?
| Phenanthrenes | 1 | 2024 | 12 | 0.230 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2005 | 99 | 0.230 |
Why?
| Diterpenes | 1 | 2024 | 32 | 0.230 |
Why?
| Epoxy Compounds | 1 | 2024 | 32 | 0.230 |
Why?
| Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.230 |
Why?
| Gene Rearrangement | 1 | 2025 | 145 | 0.220 |
Why?
| Abnormalities, Multiple | 1 | 2005 | 178 | 0.220 |
Why?
| Female | 25 | 2025 | 68127 | 0.220 |
Why?
| Survival Rate | 5 | 2020 | 1872 | 0.220 |
Why?
| Drug Resistance, Neoplasm | 2 | 2019 | 749 | 0.210 |
Why?
| Metencephalon | 1 | 2022 | 1 | 0.210 |
Why?
| Cell Lineage | 2 | 2022 | 333 | 0.200 |
Why?
| Disease-Free Survival | 3 | 2016 | 656 | 0.200 |
Why?
| von Willebrand Diseases | 1 | 2022 | 17 | 0.200 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.200 |
Why?
| von Willebrand Factor | 1 | 2022 | 62 | 0.190 |
Why?
| Genome, Human | 3 | 2014 | 392 | 0.190 |
Why?
| DNA Copy Number Variations | 4 | 2021 | 169 | 0.190 |
Why?
| Spheroids, Cellular | 2 | 2012 | 70 | 0.190 |
Why?
| Radiation | 1 | 2021 | 24 | 0.190 |
Why?
| Pyridines | 3 | 2019 | 469 | 0.180 |
Why?
| Neural Stem Cells | 2 | 2012 | 137 | 0.180 |
Why?
| Tumor Microenvironment | 2 | 2022 | 618 | 0.180 |
Why?
| Mice, Transgenic | 3 | 2021 | 2069 | 0.180 |
Why?
| RNA, Long Noncoding | 2 | 2021 | 178 | 0.170 |
Why?
| Fatal Outcome | 1 | 2021 | 301 | 0.170 |
Why?
| Receptor, EphB4 | 1 | 2020 | 36 | 0.170 |
Why?
| Antigens, Surface | 2 | 1997 | 150 | 0.170 |
Why?
| Ephrin-B2 | 1 | 2020 | 50 | 0.170 |
Why?
| Colony-Forming Units Assay | 2 | 2012 | 90 | 0.170 |
Why?
| Craniospinal Irradiation | 1 | 2019 | 5 | 0.170 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 69 | 0.170 |
Why?
| Oncogene Proteins, Fusion | 2 | 2019 | 198 | 0.170 |
Why?
| Receptors, Nerve Growth Factor | 1 | 2019 | 16 | 0.160 |
Why?
| RNA, Small Nuclear | 1 | 2019 | 36 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 3 | 2017 | 1943 | 0.160 |
Why?
| Karyopherins | 1 | 2019 | 17 | 0.160 |
Why?
| Kaplan-Meier Estimate | 3 | 2017 | 857 | 0.160 |
Why?
| Benzamides | 3 | 2019 | 194 | 0.160 |
Why?
| Proteins | 3 | 2021 | 936 | 0.160 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2021 | 815 | 0.150 |
Why?
| Infant | 12 | 2021 | 8913 | 0.150 |
Why?
| Adolescent | 12 | 2021 | 20213 | 0.150 |
Why?
| Cell Self Renewal | 1 | 2019 | 54 | 0.150 |
Why?
| Phenotype | 3 | 2024 | 3050 | 0.150 |
Why?
| Male | 20 | 2021 | 62883 | 0.150 |
Why?
| Neoplasms | 2 | 2025 | 2465 | 0.150 |
Why?
| Base Sequence | 4 | 2012 | 2134 | 0.150 |
Why?
| Chemoradiotherapy | 1 | 2019 | 209 | 0.150 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 215 | 0.140 |
Why?
| Everolimus | 1 | 2017 | 68 | 0.140 |
Why?
| Cohort Studies | 6 | 2021 | 5369 | 0.140 |
Why?
| Sulfonamides | 2 | 2022 | 500 | 0.140 |
Why?
| DNA Damage | 2 | 2017 | 364 | 0.140 |
Why?
| Genes, p16 | 1 | 2017 | 20 | 0.140 |
Why?
| Recombinational DNA Repair | 1 | 2017 | 12 | 0.140 |
Why?
| E2F Transcription Factors | 1 | 2017 | 59 | 0.140 |
Why?
| DNA Methylation | 4 | 2021 | 604 | 0.140 |
Why?
| Phthalazines | 1 | 2017 | 39 | 0.140 |
Why?
| Morpholines | 1 | 2017 | 125 | 0.140 |
Why?
| Cell Division | 2 | 2010 | 779 | 0.140 |
Why?
| Chloroquine | 1 | 2017 | 52 | 0.130 |
Why?
| Stem Cells | 1 | 2021 | 578 | 0.130 |
Why?
| Chromosome Aberrations | 1 | 2017 | 147 | 0.130 |
Why?
| Benzodiazepinones | 1 | 2016 | 16 | 0.130 |
Why?
| Up-Regulation | 2 | 2016 | 826 | 0.130 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.130 |
Why?
| Electric Stimulation Therapy | 1 | 2017 | 60 | 0.130 |
Why?
| Microarray Analysis | 2 | 2017 | 121 | 0.130 |
Why?
| Urea | 1 | 2016 | 75 | 0.130 |
Why?
| Immunophenotyping | 1 | 2017 | 312 | 0.130 |
Why?
| Neoplasm Invasiveness | 2 | 2020 | 480 | 0.130 |
Why?
| Thiophenes | 1 | 2016 | 119 | 0.120 |
Why?
| Lysine | 2 | 2020 | 278 | 0.120 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 421 | 0.120 |
Why?
| Survival Analysis | 2 | 2010 | 1265 | 0.120 |
Why?
| Mitosis | 1 | 2016 | 178 | 0.120 |
Why?
| In Situ Hybridization, Fluorescence | 3 | 2025 | 313 | 0.120 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 186 | 0.120 |
Why?
| Tumor Suppressor Proteins | 1 | 2017 | 312 | 0.120 |
Why?
| Genomics | 3 | 2017 | 716 | 0.120 |
Why?
| Cancer Survivors | 1 | 2019 | 263 | 0.120 |
Why?
| HeLa Cells | 1 | 2016 | 603 | 0.120 |
Why?
| Promoter Regions, Genetic | 3 | 2017 | 1199 | 0.120 |
Why?
| Lymphocyte Activation | 2 | 2002 | 1098 | 0.110 |
Why?
| Retrospective Studies | 6 | 2025 | 14460 | 0.110 |
Why?
| Indoles | 1 | 2017 | 367 | 0.110 |
Why?
| Brain | 2 | 2020 | 2618 | 0.110 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 190 | 0.110 |
Why?
| Flow Cytometry | 2 | 2019 | 1141 | 0.110 |
Why?
| Precision Medicine | 1 | 2017 | 383 | 0.110 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 773 | 0.110 |
Why?
| Phosphorylation | 4 | 2020 | 1681 | 0.100 |
Why?
| Cell Movement | 2 | 2020 | 937 | 0.100 |
Why?
| Cathepsin B | 1 | 2012 | 14 | 0.100 |
Why?
| Wnt Proteins | 1 | 2014 | 126 | 0.100 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.100 |
Why?
| Argonaute Proteins | 1 | 2012 | 28 | 0.100 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 132 | 0.100 |
Why?
| Genomic Structural Variation | 1 | 2012 | 12 | 0.100 |
Why?
| Acetylcysteine | 1 | 2013 | 144 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 206 | 0.100 |
Why?
| Luciferases | 1 | 2012 | 147 | 0.100 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 136 | 0.100 |
Why?
| Gene Expression Regulation | 1 | 2021 | 2506 | 0.100 |
Why?
| Quality of Life | 2 | 2023 | 2680 | 0.100 |
Why?
| Colorado | 1 | 2022 | 4392 | 0.100 |
Why?
| Carrier Proteins | 2 | 2012 | 731 | 0.090 |
Why?
| Carcinogenesis | 2 | 2025 | 209 | 0.090 |
Why?
| Tubulin | 1 | 2012 | 138 | 0.090 |
Why?
| Telomerase | 1 | 2013 | 231 | 0.090 |
Why?
| Interleukin-6 | 1 | 2015 | 716 | 0.090 |
Why?
| Acetylation | 1 | 2011 | 236 | 0.090 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2012 | 125 | 0.090 |
Why?
| RNA Interference | 1 | 2012 | 440 | 0.090 |
Why?
| Adenosine | 1 | 2012 | 211 | 0.090 |
Why?
| Acetaminophen | 1 | 2013 | 249 | 0.090 |
Why?
| Radiosurgery | 1 | 2014 | 317 | 0.090 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2017 | 591 | 0.090 |
Why?
| Aging | 1 | 2020 | 1770 | 0.090 |
Why?
| Tyrosine | 2 | 2023 | 216 | 0.080 |
Why?
| Ki-67 Antigen | 2 | 2022 | 106 | 0.080 |
Why?
| Hydroxamic Acids | 2 | 2007 | 88 | 0.080 |
Why?
| Neoplasm Grading | 2 | 2021 | 282 | 0.080 |
Why?
| Superoxides | 1 | 2010 | 196 | 0.080 |
Why?
| Disease Models, Animal | 1 | 2019 | 3943 | 0.080 |
Why?
| Gene Silencing | 2 | 2007 | 185 | 0.080 |
Why?
| T-Lymphocytes | 1 | 1997 | 1922 | 0.080 |
Why?
| Kidney Neoplasms | 1 | 2013 | 349 | 0.080 |
Why?
| Histone Demethylases | 2 | 2022 | 31 | 0.080 |
Why?
| Cluster Analysis | 3 | 2017 | 478 | 0.070 |
Why?
| Down-Regulation | 1 | 2010 | 629 | 0.070 |
Why?
| Syndrome | 2 | 2005 | 335 | 0.070 |
Why?
| Nerve Tissue Proteins | 2 | 2012 | 567 | 0.070 |
Why?
| Scrotum | 1 | 2006 | 26 | 0.070 |
Why?
| Young Adult | 5 | 2021 | 12320 | 0.060 |
Why?
| Premedication | 1 | 2005 | 40 | 0.060 |
Why?
| Exocrine Pancreatic Insufficiency | 1 | 2005 | 20 | 0.060 |
Why?
| Transplantation Chimera | 1 | 2005 | 54 | 0.060 |
Why?
| Anemia, Aplastic | 1 | 2005 | 33 | 0.060 |
Why?
| Drug Synergism | 2 | 2017 | 358 | 0.060 |
Why?
| Computer Simulation | 2 | 2021 | 939 | 0.060 |
Why?
| RNA | 1 | 2012 | 881 | 0.060 |
Why?
| Neuroblastoma | 1 | 2006 | 154 | 0.060 |
Why?
| Molecular Sequence Data | 2 | 2008 | 2818 | 0.060 |
Why?
| Testicular Neoplasms | 1 | 2006 | 102 | 0.060 |
Why?
| Tissue Fixation | 1 | 2025 | 34 | 0.060 |
Why?
| Paraffin Embedding | 1 | 2025 | 27 | 0.060 |
Why?
| Neutropenia | 1 | 2005 | 136 | 0.060 |
Why?
| Formaldehyde | 1 | 2025 | 57 | 0.060 |
Why?
| Case-Control Studies | 1 | 2012 | 3326 | 0.060 |
Why?
| Transplantation Conditioning | 1 | 2005 | 164 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2266 | 0.060 |
Why?
| Treatment Outcome | 4 | 2024 | 10163 | 0.060 |
Why?
| Prodrugs | 1 | 2024 | 45 | 0.060 |
Why?
| Chromosomes | 1 | 2024 | 101 | 0.050 |
Why?
| Organophosphates | 1 | 2024 | 120 | 0.050 |
Why?
| Graft vs Host Disease | 1 | 2005 | 237 | 0.050 |
Why?
| Fluorouracil | 1 | 2024 | 197 | 0.050 |
Why?
| Core Binding Factor alpha Subunits | 1 | 2022 | 2 | 0.050 |
Why?
| Graft Survival | 1 | 2005 | 503 | 0.050 |
Why?
| Otx Transcription Factors | 1 | 2022 | 13 | 0.050 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2023 | 160 | 0.050 |
Why?
| Weibel-Palade Bodies | 1 | 2022 | 3 | 0.050 |
Why?
| fas Receptor | 1 | 2002 | 95 | 0.050 |
Why?
| Lymphoproliferative Disorders | 1 | 2002 | 53 | 0.050 |
Why?
| T-Box Domain Proteins | 1 | 2022 | 96 | 0.050 |
Why?
| Gene Ontology | 1 | 2021 | 48 | 0.050 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 97 | 0.050 |
Why?
| Antigens, CD | 3 | 2002 | 479 | 0.050 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 235 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 57 | 0.050 |
Why?
| RNA Polymerase II | 1 | 2024 | 313 | 0.050 |
Why?
| Phagocytosis | 1 | 2023 | 364 | 0.040 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 425 | 0.040 |
Why?
| Muscle Proteins | 1 | 2022 | 228 | 0.040 |
Why?
| Ifosfamide | 1 | 2020 | 34 | 0.040 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 215 | 0.040 |
Why?
| Follow-Up Studies | 2 | 2019 | 4898 | 0.040 |
Why?
| Transcription Factor HES-1 | 1 | 2019 | 5 | 0.040 |
Why?
| Smoothened Receptor | 1 | 2019 | 6 | 0.040 |
Why?
| Risk Factors | 3 | 2021 | 9727 | 0.040 |
Why?
| MyoD Protein | 1 | 2019 | 32 | 0.040 |
Why?
| Gain of Function Mutation | 1 | 2019 | 33 | 0.040 |
Why?
| Cyclophosphamide | 1 | 2020 | 231 | 0.040 |
Why?
| Astrocytoma | 1 | 2020 | 120 | 0.040 |
Why?
| RNA Splice Sites | 1 | 2019 | 44 | 0.040 |
Why?
| Apoptosis Regulatory Proteins | 2 | 1997 | 182 | 0.040 |
Why?
| Adult | 5 | 2021 | 35315 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 345 | 0.040 |
Why?
| Aminopyridines | 1 | 2019 | 96 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 281 | 0.040 |
Why?
| Autoimmune Diseases | 1 | 2002 | 423 | 0.040 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 1997 | 226 | 0.040 |
Why?
| RNA Splicing | 1 | 2019 | 258 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 582 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2002 | 701 | 0.040 |
Why?
| Consensus | 1 | 2021 | 633 | 0.040 |
Why?
| Drug Approval | 1 | 2018 | 86 | 0.040 |
Why?
| Transcription, Genetic | 1 | 2024 | 1398 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 26 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 20 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 58 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 34 | 0.040 |
Why?
| Alternative Splicing | 1 | 2019 | 218 | 0.040 |
Why?
| Homeodomain Proteins | 1 | 2021 | 487 | 0.030 |
Why?
| Transfection | 1 | 2019 | 895 | 0.030 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1997 | 150 | 0.030 |
Why?
| DNA, Complementary | 1 | 1997 | 267 | 0.030 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 115 | 0.030 |
Why?
| Jurkat Cells | 1 | 1997 | 131 | 0.030 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 93 | 0.030 |
Why?
| Global Health | 1 | 2019 | 326 | 0.030 |
Why?
| Radiotherapy | 1 | 2017 | 185 | 0.030 |
Why?
| Microscopy, Confocal | 1 | 2017 | 308 | 0.030 |
Why?
| Genetic Variation | 1 | 2021 | 934 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 355 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 345 | 0.030 |
Why?
| Macrophages | 1 | 2023 | 1463 | 0.030 |
Why?
| Canada | 1 | 2016 | 345 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 88 | 0.030 |
Why?
| Health Status | 1 | 2019 | 751 | 0.030 |
Why?
| Zinc Finger Protein Gli2 | 1 | 2014 | 4 | 0.030 |
Why?
| Hematopoietic Stem Cells | 1 | 1997 | 377 | 0.030 |
Why?
| Cytogenetics | 1 | 2014 | 12 | 0.030 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2014 | 18 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2014 | 56 | 0.030 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2014 | 56 | 0.030 |
Why?
| Myeloid Cells | 1 | 2015 | 142 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 534 | 0.030 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2014 | 66 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 66 | 0.030 |
Why?
| Gene Expression | 2 | 2010 | 1462 | 0.030 |
Why?
| Middle Aged | 3 | 2021 | 30893 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 168 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2017 | 1669 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2016 | 3366 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2013 | 386 | 0.020 |
Why?
| Gene Duplication | 1 | 2012 | 68 | 0.020 |
Why?
| Monocytes | 1 | 2015 | 541 | 0.020 |
Why?
| Translocation, Genetic | 1 | 2012 | 97 | 0.020 |
Why?
| Methylation | 1 | 2012 | 227 | 0.020 |
Why?
| B-Lymphocytes | 1 | 1997 | 820 | 0.020 |
Why?
| Inflammation Mediators | 1 | 2015 | 500 | 0.020 |
Why?
| Inflammation | 1 | 2023 | 2664 | 0.020 |
Why?
| Glutathione | 1 | 2013 | 334 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 5257 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2014 | 1208 | 0.020 |
Why?
| Genome | 1 | 2012 | 277 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2012 | 448 | 0.020 |
Why?
| Age Factors | 1 | 2017 | 3117 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1936 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1831 | 0.020 |
Why?
| Disease Progression | 1 | 2016 | 2603 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2019 | 5346 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 1985 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2014 | 3023 | 0.020 |
Why?
| Azacitidine | 1 | 2006 | 140 | 0.010 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2012 | 2065 | 0.010 |
Why?
| Risk Assessment | 1 | 2014 | 3256 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2521 | 0.010 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 87 | 0.010 |
Why?
| Receptors, Interleukin-2 | 1 | 2002 | 65 | 0.010 |
Why?
| Lectins, C-Type | 1 | 2002 | 64 | 0.010 |
Why?
| Cytoplasm | 1 | 2002 | 258 | 0.010 |
Why?
| Interleukin-4 | 1 | 2002 | 213 | 0.010 |
Why?
| Interleukin-2 | 1 | 2002 | 430 | 0.010 |
Why?
| Infant, Newborn | 1 | 2011 | 5687 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 2002 | 410 | 0.010 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2002 | 374 | 0.010 |
Why?
| Interferon-gamma | 1 | 2002 | 761 | 0.010 |
Why?
| Restriction Mapping | 1 | 1997 | 74 | 0.010 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 1997 | 28 | 0.010 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 1997 | 149 | 0.010 |
Why?
| Interleukin-7 | 1 | 1997 | 59 | 0.010 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1997 | 87 | 0.010 |
Why?
| Genes | 1 | 1997 | 226 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 1997 | 368 | 0.010 |
Why?
| Calcium | 1 | 2002 | 1178 | 0.010 |
Why?
| Bone Marrow | 1 | 1997 | 267 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1997 | 1229 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1997 | 2041 | 0.010 |
Why?
| Cells, Cultured | 1 | 1997 | 4008 | 0.010 |
Why?
|
|
Vibhakar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|